Cargando…

Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States

IMPORTANCE: Thyroid eye disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of life (QoL), producing possibly substantial visual changes, disfigurement, and disability. OBJECTIVE: To determine the association of varying TED severities with QoL in a non-TED...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Terry J., Cockerham, Kimberly, Lelli, Gary, Choudhary, Chitra, Taylor, Stephanie, Barretto, Naina, Enstone, Ashley, Oliver, Louisa, Lynch, Judah, Holt, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857514/
https://www.ncbi.nlm.nih.gov/pubmed/36580313
http://dx.doi.org/10.1001/jamaophthalmol.2022.3225
_version_ 1784873886341398528
author Smith, Terry J.
Cockerham, Kimberly
Lelli, Gary
Choudhary, Chitra
Taylor, Stephanie
Barretto, Naina
Enstone, Ashley
Oliver, Louisa
Lynch, Judah
Holt, Robert J.
author_facet Smith, Terry J.
Cockerham, Kimberly
Lelli, Gary
Choudhary, Chitra
Taylor, Stephanie
Barretto, Naina
Enstone, Ashley
Oliver, Louisa
Lynch, Judah
Holt, Robert J.
author_sort Smith, Terry J.
collection PubMed
description IMPORTANCE: Thyroid eye disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of life (QoL), producing possibly substantial visual changes, disfigurement, and disability. OBJECTIVE: To determine the association of varying TED severities with QoL in a non-TED population by assessing health state utility scores. DESIGN, SETTING, AND PARTICIPANTS: This qualitative study, conducted from April 20, 2020, to April 29, 2021, assessed health states for active, moderate-severe TED, and values were elicited using time trade-off methods. Six health states of varying severity were determined from 2 placebo-controlled clinical trials (171 patients with TED and clinical activity score ≥4, ±diplopia/proptosis) and refined using interviews with US patients with TED (n = 6). Each health state description was validated by interviews with additional TED patient advocates (n = 3) and physician experts (n = 3). Health state descriptions and a QOL questionnaire were piloted and administered to a general population. Visual analog scales (VASs) were also administered to detect concurrence of the findings. MAIN OUTCOMES AND MEASURES: TED health state utility scores and whether they differ from one another were assessed using Shapiro-Wilk, Kruskal-Wallis, pairwise Wilcoxon rank sum, and paired t tests. RESULTS: A total of 111 participants completed time trade-off interviews. The mean (SD) utility value was 0.44 (0.34). The lowest (worse) mean utility value was observed in the most severe disease state (constant diplopia/large proptosis) with 0.30 (95% CI, 0.24-0.36), followed by constant diplopia/small proptosis (0.34; 95% CI, 0.29-0.40), intermittent or inconstant diplopia/large proptosis (0.43; 95% CI, 0.36-0.49), no diplopia/large proptosis (0.46; 95% CI, 0.40-0.52), and intermittent or inconstant diplopia/small proptosis (0.52; 95% CI, 0.45-0.58). The highest (best) mean value, 0.60 (95% CI, 0.54-0.67), was observed for the least severe disease state (no diplopia/small proptosis). CONCLUSIONS AND RELEVANCE: These findings suggest that patients with active, moderate-severe TED may have substantial disutility, with increasing severity of proptosis/diplopia more likely to have detrimental associations with QoL. These health state scores may provide a baseline for determining QoL improvement in these TED health states (utility gains) treated with new therapies.
format Online
Article
Text
id pubmed-9857514
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-98575142023-02-17 Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States Smith, Terry J. Cockerham, Kimberly Lelli, Gary Choudhary, Chitra Taylor, Stephanie Barretto, Naina Enstone, Ashley Oliver, Louisa Lynch, Judah Holt, Robert J. JAMA Ophthalmol Original Investigation IMPORTANCE: Thyroid eye disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of life (QoL), producing possibly substantial visual changes, disfigurement, and disability. OBJECTIVE: To determine the association of varying TED severities with QoL in a non-TED population by assessing health state utility scores. DESIGN, SETTING, AND PARTICIPANTS: This qualitative study, conducted from April 20, 2020, to April 29, 2021, assessed health states for active, moderate-severe TED, and values were elicited using time trade-off methods. Six health states of varying severity were determined from 2 placebo-controlled clinical trials (171 patients with TED and clinical activity score ≥4, ±diplopia/proptosis) and refined using interviews with US patients with TED (n = 6). Each health state description was validated by interviews with additional TED patient advocates (n = 3) and physician experts (n = 3). Health state descriptions and a QOL questionnaire were piloted and administered to a general population. Visual analog scales (VASs) were also administered to detect concurrence of the findings. MAIN OUTCOMES AND MEASURES: TED health state utility scores and whether they differ from one another were assessed using Shapiro-Wilk, Kruskal-Wallis, pairwise Wilcoxon rank sum, and paired t tests. RESULTS: A total of 111 participants completed time trade-off interviews. The mean (SD) utility value was 0.44 (0.34). The lowest (worse) mean utility value was observed in the most severe disease state (constant diplopia/large proptosis) with 0.30 (95% CI, 0.24-0.36), followed by constant diplopia/small proptosis (0.34; 95% CI, 0.29-0.40), intermittent or inconstant diplopia/large proptosis (0.43; 95% CI, 0.36-0.49), no diplopia/large proptosis (0.46; 95% CI, 0.40-0.52), and intermittent or inconstant diplopia/small proptosis (0.52; 95% CI, 0.45-0.58). The highest (best) mean value, 0.60 (95% CI, 0.54-0.67), was observed for the least severe disease state (no diplopia/small proptosis). CONCLUSIONS AND RELEVANCE: These findings suggest that patients with active, moderate-severe TED may have substantial disutility, with increasing severity of proptosis/diplopia more likely to have detrimental associations with QoL. These health state scores may provide a baseline for determining QoL improvement in these TED health states (utility gains) treated with new therapies. American Medical Association 2022-12-29 2023-02 /pmc/articles/PMC9857514/ /pubmed/36580313 http://dx.doi.org/10.1001/jamaophthalmol.2022.3225 Text en Copyright 2022 Smith TJ et al. JAMA Ophthalmology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License.
spellingShingle Original Investigation
Smith, Terry J.
Cockerham, Kimberly
Lelli, Gary
Choudhary, Chitra
Taylor, Stephanie
Barretto, Naina
Enstone, Ashley
Oliver, Louisa
Lynch, Judah
Holt, Robert J.
Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States
title Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States
title_full Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States
title_fullStr Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States
title_full_unstemmed Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States
title_short Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States
title_sort utility assessment of moderate to severe thyroid eye disease health states
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857514/
https://www.ncbi.nlm.nih.gov/pubmed/36580313
http://dx.doi.org/10.1001/jamaophthalmol.2022.3225
work_keys_str_mv AT smithterryj utilityassessmentofmoderatetoseverethyroideyediseasehealthstates
AT cockerhamkimberly utilityassessmentofmoderatetoseverethyroideyediseasehealthstates
AT lelligary utilityassessmentofmoderatetoseverethyroideyediseasehealthstates
AT choudharychitra utilityassessmentofmoderatetoseverethyroideyediseasehealthstates
AT taylorstephanie utilityassessmentofmoderatetoseverethyroideyediseasehealthstates
AT barrettonaina utilityassessmentofmoderatetoseverethyroideyediseasehealthstates
AT enstoneashley utilityassessmentofmoderatetoseverethyroideyediseasehealthstates
AT oliverlouisa utilityassessmentofmoderatetoseverethyroideyediseasehealthstates
AT lynchjudah utilityassessmentofmoderatetoseverethyroideyediseasehealthstates
AT holtrobertj utilityassessmentofmoderatetoseverethyroideyediseasehealthstates